Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eye movement desensitization and reprocessing therapy versus supportive therapy in affective relapse prevention in bipolar patients with a history of trauma: study protocol for a randomized controlled trial.
Moreno-Alcázar A, Radua J, Landín-Romero R, Blanco L, Madre M, Reinares M, Comes M, Jiménez E, Crespo JM, Vieta E, Pérez V, Novo P, Doñate M, Cortizo R, Valiente-Gómez A, Lupo W, McKenna PJ, Pomarol-Clotet E, Amann BL. Moreno-Alcázar A, et al. Among authors: novo p. Trials. 2017 Apr 4;18(1):160. doi: 10.1186/s13063-017-1910-y. Trials. 2017. PMID: 28376919 Free PMC article. Clinical Trial.
Implementing Programs to Initiate Buprenorphine for Opioid Use Disorder Treatment in High-Need, Low-Resource Emergency Departments: A Nonrandomized Controlled Trial.
McCormack RP, Rotrosen J, Gauthier P, D'Onofrio G, Fiellin DA, Marsch LA, Novo P, Liu D, Edelman EJ, Farkas S, Matthews AG, Mulatya C, Salazar D, Wolff J, Knight R, Goodman W, Williams J, Hawk K. McCormack RP, et al. Among authors: novo p. Ann Emerg Med. 2023 Sep;82(3):272-287. doi: 10.1016/j.annemergmed.2023.02.013. Epub 2023 May 2. Ann Emerg Med. 2023. PMID: 37140493 Free article. Clinical Trial.
Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorder.
Hefner K, Choo TH, Shmueli-Blumberg D, Pavlicova M, King J, Fishman M, Shulman M, Campbell A, Greiner M, Scodes J, Meyers-Ohki S, Novo P, Nunes E, Rotrosen J. Hefner K, et al. Among authors: novo p. Drug Alcohol Depend Rep. 2022 Dec;5:100100. doi: 10.1016/j.dadr.2022.100100. Epub 2022 Sep 29. Drug Alcohol Depend Rep. 2022. PMID: 36644220 Free PMC article.
Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial.
Shulman M, Provost S, Ohrtman K, Novo P, Meyers-Ohki S, Van Veldhuisen P, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Nunes EV, Weiss RD. Shulman M, et al. Among authors: novo p. Contemp Clin Trials. 2024 Apr 23;142:107543. doi: 10.1016/j.cct.2024.107543. Online ahead of print. Contemp Clin Trials. 2024. PMID: 38657730
Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence.
Nunes EV, Lee JD, Sisti D, Segal A, Caplan A, Fishman M, Bailey G, Brigham G, Novo P, Farkas S, Rotrosen J. Nunes EV, et al. Among authors: novo p. Contemp Clin Trials. 2016 Nov;51:34-43. doi: 10.1016/j.cct.2016.09.006. Epub 2016 Sep 28. Contemp Clin Trials. 2016. PMID: 27687743 Free PMC article.
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J, Lindblad R, Liu D, Matthews AG, May J, Peavy KM, Ross S, Salazar D, Schkolnik P, Shmueli-Blumberg D, Stablein D, Subramaniam G, Rotrosen J. Lee JD, et al. Among authors: novo p. Lancet. 2018 Jan 27;391(10118):309-318. doi: 10.1016/S0140-6736(17)32812-X. Epub 2017 Nov 14. Lancet. 2018. PMID: 29150198 Free PMC article. Clinical Trial.
Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial.
Campbell ANC, Barbosa-Leiker C, Hatch-Maillette M, Mennenga SE, Pavlicova M, Scodes J, Saraiya T, Mitchell SG, Rotrosen J, Novo P, Nunes EV, Greenfield SF. Campbell ANC, et al. Among authors: novo p. Am J Addict. 2018 Sep;27(6):465-470. doi: 10.1111/ajad.12784. Epub 2018 Aug 14. Am J Addict. 2018. PMID: 30106494 Free PMC article. Clinical Trial.
55 results